Please provide your email address to receive an email when new articles are posted on . In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ...
Safety of fruquintinib monotherapy and combination therapy in Chinese patients with colorectal cancer in real-world clinical practice: A subgroup analysis from phase IV study. This is an ASCO Meeting ...
Panakeia (“the Company”), a pioneer in AI-driven multi-omic biomarker profiling, today announces the launch of PANProfiler Colon, an AI-driven software solution for profiling of Microsatellite ...
When Vanessa was diagnosed with advanced colon cancer in 2014, just before her 60th birthday, the mother and grandmother learned the cancer had already spread to her stomach and liver. Even after a ...
Mismatch repair–deficient (dMMR) tumors can be found in 10 to 15% of patients with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited. The use of neoadjuvant ...
Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in the risk of disease progression or death by 79% vs. chemotherapy in the first-line setting and by 38% vs. Opdivo ...
ABT-301, an HDAC1/2/3 inhibitor, enhances immune response and tumor microenvironment, potentially improving immune checkpoint inhibitor efficacy in metastatic colorectal cancer. The phase 1/2 trial ...
Hosted on MSN
AI model simultaneously detects multiple genetic colorectal cancer markers in tissue samples
A multicenter study has analyzed nearly 2,000 digitized tissue slides from colon cancer patients across seven independent cohorts in Europe and the US. The samples included both whole-slide images of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback